Hypothyroidism associated with aminoglutethimide in patients with prostate cancer
Abstract
OBJECTIVE: The administration of aminoglutethimide and hydrocortisone is a second-line hormonal maneuver commonly prescribed for the treatment of metastatic prostate cancer. We determine the incidence of aminoglutethimide-induced primary hypothyroidism in an elderly population who have prostate cancer. DESIGN: Prospective evaluation. PATIENTS: Twenty-nine men with stage D2 prostate cancer who were treated at the National Cancer Institute, Bethesda, Md, in 1992. RESULTS: Clinical and biochemical evidence of hypothyroidism (thyrotropin levels greater than 10 mU/L) was noted in nine of 29 patients treated following the initiation of aminoglutethimide (250 mg four times daily). The elevation in thyrotropin and the clinical symptoms of hypothyroidism were reversed by the administration of levothyroxine (n = 4). CONCLUSION: Hypothyroidism should be included in the differential diagnosis of lethargy in elderly patients who are receiving aminoglutethimide for prostate cancer. Furthermore, patients who are receiving this agent at a dosage of 1000 mg/d or greater should have their serum thyrotropin levels monitored, and replacement therapy with levothyroxine should be initiated when abnormally elevated levels are noted.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Of 29 aminoglutethimide-treated patients with prostate cancer, nine (31%) developed hypothyroidism (TSH >10 mU/L).
“Of 29 aminoglutethimide-treated patients with prostate cancer, nine (31%) developed hypothyroidism (TSH >10 mU/L) (67).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [67]
Cites
Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome
Kelly, W. K., & Scher, H. I. (1993) · The Journal of Urology · doi:10.1016/s0022-5347(17)36163-3 · Cited by 352 · see citing works
de MOURA, A. (1962) · PubMed · Cited by 289 · see citing works
Sartor, O. A., Cooper, M. R., Weinberger, M., Headlee, D. J., Thibault, A., Tompkins, A. C., Steinberg, S. M., Figg, W. D., Linehan, W. M., & Myers, C. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.3.222 · Cited by 134 · see citing works
Self-citationAminoglutethimide: Review of Pharmacology and Clinical Use
Santen, R. J., & Misbin, R. I. (1981) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1981.tb03557.x · Cited by 110 · see citing works
Aminoglutethimide: a ‘side-effect’ turned to therapeutic advantage
Hughes, S. W. M., & Burley, D. M. (1970) · Postgraduate Medical Journal · doi:10.1136/pgmj.46.537.409 · Cited by 87 · see citing works
Management of progressive metastatic prostate cancer.
Waselenko, J. K., & Dawson, N. A. (1993) · PubMed · Cited by 55 · see citing works
Santen, R. J., Wells, S. A., COHN, N., Demers, L. M., Misbin, R. I., & Foltz, E. L. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-4-739 · Cited by 41 · see citing works
Goitrous Hypothyroidism Induced by Amino-glutethimide, Anticonvulsant Drug
Rallison, M. L., Kumagai, L. F., & Tyler, F. H. (1967) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-27-2-265 · Cited by 40 · see citing works
Antithyroid and Antiadrenocortical Activity of Aminoglutethimide
Pittman, J. A., & BROWN, R. W. (1966) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-26-9-1014 · Cited by 30 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
L-T4 therapy in the presence of pharmacological interferents
Benvenga, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607446 · Cited by 13 · see citing works
“Of 29 aminoglutethimide-treated patients with prostate cancer, nine (31%) developed hypothyroidism (TSH >10 mU/L) (67).”
Background
- Authors
- Figg, W. D.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Figg, William D.
- ORCID
- Figg, William D.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1994-05-09
- Volume
- 154
- Issue
- 9
- Pages
- 1023
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2024604661
- Cited by
- 10
- References
- 9
- Citations by year
- 2020: 1 · 2015: 1 · 2013: 1
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Keywords
- aminoglutethimide, hypothyroidism, prostate cancer, metastatic prostate cancer, thyroid-stimulating hormone, levothyroxine, drug-induced hypothyroidism, cortisol, elderly patients, lethargy
- MeSH terms
- Aged, Aminoglutethimide, Diagnosis, Differential, Humans, Hypothyroidism, Male, Prospective Studies, Prostatic Neoplasms, Thyrotropin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
